TickerTalks
Browse all tickers →
TickerTalks›$PFE
PFPFE

Pfizer Inc.

$PFE·$138B·Drug Manufacturers - General·Healthcare
$25.05-0.4%YTD+0.3%1Y+1.9%
Mentions · last 7 days
2026-07-10: 415 posts2026-07-11: 151 posts2026-07-12: 301 posts2026-07-13: 341 posts2026-07-14: 213 posts2026-07-15: 356 posts2026-07-16: 286 posts2,141-3%
Price updated 5h ago·X counts updated 1d ago
PFPFE
$PFEPfizer Inc.
$25.05-0.36%2.1k posts-3%
AI analysisFundamentalsVoices on X
Loading…

AI verdict & sentimentAI analysisGenerated by AI from underlying data

Top X posts

Today's AI verdict on what's driving $PFE, plus how loud the X conversation is and which way it's leaning.

AI analysis

TickerTalks’ read on the fundamentals and what’s driving the move.

Broken storyStalledAI verdict · as of 2026-07-17

The move has stalled — likely just drifts unless something new shows up.

Pharma giant stuck at pandemic-era lows with a departing CFO and no obesity leg to lean on.

Pfizer is the diversified pharma with a legacy vaccines franchise (Comirnaty, Prevnar), a real oncology portfolio (Seagen deal), and a dividend that the market treats as the primary reason to hold the stock. The problem is the equity keeps failing to compound and every leg of the recovery narrative has slipped.

Why the tape refuses to reward:

  • The top line is barely moving: Q1 revenue grew 5% YoY off an easier COVID-collapse comp, and management reaffirmed a wide $59.5-$62.5B FY26 revenue range — flat-to-slightly-up, not the reset the bulls have needed.
  • The multiple looks cheap but is earning the discount: 20x trailing earnings on falling EPS quality, a 6% FCF yield and consensus FY27 EPS at $2.94 — the multiple is what a market pays for a business without a growth franchise.
  • The catalyst path is closed for now: obesity has been ruled out ('CNBC: we've been saying stay away'), the CFO Dave Denton departure to consumer goods is a soft signal, and the UK Court of Appeal loss on CMA fines added a legal headline nobody wanted.
  • Insider action is nothing but director share awards — no meaningful buys from Bourla or others despite the stock at 36% of the 52-week range, which is where a confident management would signal.

The forward view: the way this stops being broken is a real obesity or immunology asset re-entering the pipeline narrative and the August 4 Q2 print stabilizing FY guidance at the upper end of the current range. Absent either, the stock has enough dividend support to prevent a real breakdown but not enough operational lift to break out — a genuine 'stalled' setup where the base case is drift. A dividend cut is the tail risk that would flip stalled to breaking-down.

Agrees with X sentimentThe bearish X read — 'squandered COVID money,' failure to enter obesity, AZN comparison also weak — is directionally right on the story. Our disagreement: bulls calling for a contrarian entry based on July seasonality alone underweight the structural pipeline gap.

What to watch: August 4 Q2 earnings and any pipeline-partnership announcement in obesity or immunology; a dividend-related headline is the tail risk that would flip stalled to breaking-down.

On the calendar: 2026-08-04 — Q2 2026 earnings

X sentiment

What the X crowd is saying right now — descriptive, summarised from the day’s posts.

Bearish sentiment8 posts analyzed · as of 2026-07-15

Pfizer chatter is bearish. PFE and Flynn Pharma lost a UK Court of Appeal ruling on CMA fines - a legal setback. Community members are frustrated with the Bourla legacy and 'squandered COVID money' criticism. PFE valuation vs AZN is being discussed but even AZN is -9% today. Bulls point to July seasonality historically being strong for PFE. Bears cite continued frustration over Pfizer's inability to enter obesity ('CNBC: we've been saying stay away'). Sentiment lean negative.

Read the AI verdict + X sentiment for $PFE

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • X crowd read with bullish/bearish call + post volume
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Makes vaccines, oncology drugs, and small-molecule medicines while rebuilding revenue after COVID product declines.

Industry overviewAI analysisGenerated by AI from underlying data

Where Drug Manufacturers - General sits in its cycle right now — and what that implies for $PFE.

Drug Manufacturers - General · Healthcare

No material change from last week — oral semaglutide versus injectable Zepbound, with Amgen, Pfizer, and AZ all presenting obesity pipeline data.

What this means for $PFE

Neutral — Makes vaccines, oncology drugs, and small-molecule medicines while rebuilding revenue after COVID product declines; this business's revenue is largely decoupled from the oral GLP-1 and obesity pipeline expansion and competition.

Top industry ETF

$IHEiShares U.S. Pharmaceuticals ETF
+18.7%YTD
+49.8%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
19.8How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
8.0%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
23.4%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
6.4%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
2.3Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
8.4%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
69.3%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
0.7Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q1 2026May 5, 2026$0.75$0.72+3.9%
Q4 2025Feb 3, 2026$0.66$0.57+16.4%
Q3 2025Nov 4, 2025$0.87$0.63+37.4%
Q2 2025Aug 5, 2025$0.78$0.58+34.5%
Next earningsTue, Aug 4·consensus EPS $0.68

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q1 FY26$14.5B+5.4%67.3%27.9%$0.47$2.2B
Q4 FY25$17.6B-1.2%70.0%21.0%$-0.29$4.5B
Q3 FY25$16.7B-5.9%74.9%21.3%$0.62$4.0B
Q2 FY25$14.7B+10.3%64.3%24.4%$0.51$-1.2B

Forward consensus

5-year forecast · up to 22 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$61.8B$60.7B – $62.7B$2.95$2.86 – $3.0319
FY27$59.2B$56.4B – $60.9B$2.82$2.59 – $2.9819
FY28$54.7B$54.3B – $55.0B$2.42$1.53 – $2.7622
FY29$53.2B$51.1B – $54.9B$2.27$2.15 – $2.3615
FY30$53.5B$51.5B – $55.3B$2.30$2.19 – $2.4011

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.0.8×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.34%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.-0.9%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.-3.2%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatMega float · 5.7B shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today0.7% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β0.315-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

SellJun 9Jennifer B. DamicoSVP & Controller2.0K sh$51K
+ 49 other (45 awards · 3 inkinds · 1 exempt) in window

See when $PFE insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

8-KPress release / Reg FDJun 188-K — Item 7.01: Press release / Reg FD
AI summary

Pfizer reaffirmed its full-year 2026 financial guidance on June 18, 2026, concurrent with the CFO departure announcement. Guidance is unchanged: revenues of $59.5–$62.5 billion and Adjusted Diluted EPS of $2.80–$3.00, consistent with the December 2025 introduction and May 5, 2026 Q1 call reaffirmation. The same-day guidance reaffirmation alongside the CFO transition is designed to signal management confidence in the financial outlook and contains investor concern from the leadership change. Stable outlook — Pfizer is holding guidance range despite a CFO departure mid-year.

8-KOfficer or director changeJun 188-K — Item 5.02: Officer or director change
AI summary

Pfizer CFO Dave Denton notified the company on June 16, 2026 that he will resign effective August 15, 2026 to pursue a role in consumer goods outside pharmaceuticals, with no disagreement over Pfizer's financial or operating results. Cecile Guegan (55), SVP Finance, Global Biopharmaceutical Business (Pfizer since 2005, current role since 2022), will serve as Interim CFO from August 16, 2026 while a comprehensive permanent search is conducted. A CFO departure mid-year is material for a large-cap pharma navigating post-COVID product portfolio transitions; the same-day guidance reaffirmation (see companion 8-K) was filed simultaneously to offset investor concern.

3/ANew insider — initial holdingsApr 273/A
AI summary

Form filed by More than One Reporting Person Table I - Non-De filed a Form 3/A (amended) for PFE on 2026-04-27, initiating required Section 16 reporting. Role: of Reporting Person. Form 3 is a mandatory administrative filing upon first becoming an insider or 10%+ holder; it does not reflect a purchase or sale event.

8-KShareholder voteApr 278-K — Item 5.07: Shareholder vote
AI summary

PFE held its Annual Meeting of stockholders around 2026-04-27 (8-K Item 5.07). Stockholders elected 11 directors to the board. Independent auditor ratification was approved. Routine governance event — monitor for unusually high withhold votes as an activist signal.

3New insider — initial holdingsApr 103
AI summary

Form filed by More than One Reporting Person Table I - Non-De filed a Form 3 (initial ownership statement) for PFE on 2026-04-10, initiating required Section 16 reporting. Role: of Reporting Person. Form 3 is a mandatory administrative filing upon first becoming an insider or 10%+ holder; it does not reflect a purchase or sale event.

SC 13D/AActivist amendmentFeb 13SC 13D/A
+ 17 other (5 13Gs · 2 11-Ks · 2 13Fs · 2 earnings 8-Ks) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

3 High-Yield Dividend Stocks to Buy and Holdfool.com·1d agoPfizer Stock Below 50-Day and 200-Day SMA: Buy the Dip or Exit Now?zacks.com·2d agoArbutus Initiates International Patent Infringement Enforcement Actions Against Pfizer and BioNTech, Receives First Payment From Moderna Settlement Agreement and Announces Intent to Return Capital to Shareholdersglobenewswire.com·2d agoStock Market Is Giving A Pristine Entry Point Into This 64-Year Dividend King247wallst.com·3d agoIs the Bearishness Around Pfizer and Gilead Sciences a Contrarian Opportunity?247wallst.com·3d ago

In themes

Explore the broader themes this ticker is being talked about under.

GLP-1 & Weight Loss

More in Drug Manufacturers - General

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$LLY$NVO$JNJ$MRK$ABBV$GILD$OGN$BMY
Voices on X · top 3 · last 7 days

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport